Stroes, Erik S2; Thompson, Paul D2; Corsini, Alberto2; Vladutiu, Georgirene D2; Raal, Frederick J2; Ray, Kausik K2; Roden, Michael2; Stein, Evan2; Tokgözoğlu, Lale2; Nordestgaard, Børge G3; Bruckert, Eric2; De Backer, Guy2; Krauss, Ronald M2; Laufs, Ulrich2; Santos, Raul D2; Hegele, Robert A2; Hovingh, G Kees2; Leiter, Lawrence A2; Mach, Francois2; März, Winfried2; Newman, Connie B2; Wiklund, Olov2; Jacobson, Terry A2; Catapano, Alberico L2; Chapman, M John2; Ginsberg, Henry N2
1 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet2 unknown3 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet
European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses. Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7-29% in registries and observational studies. Preclinical studies show that statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, thereby providing a potential link between statins and muscle symptoms; controlled mechanistic and genetic studies in humans are necessary to further understanding. The Panel proposes to identify SAMS by symptoms typical of statin myalgia (i.e. muscle pain or aching) and their temporal association with discontinuation and response to repetitive statin re-challenge. In people with SAMS, the Panel recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets. The Panel recommends a structured work-up to identify individuals with clinically relevant SAMS generally to at least three different statins, so that they can be offered therapeutic regimens to satisfactorily address their cardiovascular risk. Further research into the underlying pathophysiological mechanisms may offer future therapeutic potential.
Journal review article
European Heart Journal, 2015, Vol 36, Issue 17, p. 1012-22